Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Q3 2025 earnings

Reported November 10, 2025 · After market close

EPS-$0.52Beat by $0.14
EPS estimate-$0.66

Next report

Nov 9, 2026 (in 2 months)
EPS estimate-$0.53

Financials

Q3 2025

Income statement

See full
Operating income-$41.1M+31.6%
Net income-$36.9M+34.5%
EPS (diluted)-$0.52+54.0%

Balance sheet

See full
Cash & equivalents$1.2M+142%
Total equity$576.4M+143%
Total assets$599.9M+124%

Cash flow

See full
Operating cash flow-$28.9M+42.5%
CapEx--100%
Free cash flow-$28.9M+42.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.94B+392%

Returns & leverage

See full
Return on equity-42.1%-10.0pp
Current ratio25.5×+17.0×

FAQ

When did Mineralys Therapeutics, Inc. report Q3 2025 earnings?
Mineralys Therapeutics, Inc. (MLYS) reported Q3 2025 earnings on November 10, 2025 after market close.
What were Mineralys Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Mineralys Therapeutics, Inc. reported eps of $-0.52 for Q3 2025.
Did Mineralys Therapeutics, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.66 by $0.14.
How did Mineralys Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 54.0% from $-1.13.
Where can I find Mineralys Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001933414-25-000139) and the 10-Q periodic report (0001933414-25-000142) directly on SEC EDGAR. The filing index links above go to sec.gov.